199 related articles for article (PubMed ID: 26314506)
21. Abnormal temporal difference reward-learning signals in major depression.
Kumar P; Waiter G; Ahearn T; Milders M; Reid I; Steele JD
Brain; 2008 Aug; 131(Pt 8):2084-93. PubMed ID: 18579575
[TBL] [Abstract][Full Text] [Related]
22. Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial.
Salardini E; Zeinoddini A; Mohammadinejad P; Khodaie-Ardakani MR; Zahraei N; Zeinoddini A; Akhondzadeh S
J Psychiatr Res; 2016 Apr; 75():24-30. PubMed ID: 26800392
[TBL] [Abstract][Full Text] [Related]
23. Distribution of microRNAs associated with major depressive disorder among blood compartments.
Homorogan C; Enatescu VR; Nitusca D; Marcu A; Seclaman E; Marian C
J Int Med Res; 2021 Apr; 49(4):3000605211006633. PubMed ID: 33827323
[TBL] [Abstract][Full Text] [Related]
24. Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response.
Yu YW; Tsai SJ; Hong CJ; Chen TJ; Chen MC; Yang CW
Neuropsychopharmacology; 2005 Sep; 30(9):1719-23. PubMed ID: 15956990
[TBL] [Abstract][Full Text] [Related]
25. Dysregulation of IRAS/nischarin and other potential I
Keller B; García-Sevilla JA
J Affect Disord; 2017 Jan; 208():646-652. PubMed ID: 27836117
[TBL] [Abstract][Full Text] [Related]
26. Antidepressant Medication Prescribing Practices for Treatment of Major Depressive Disorder.
Treviño LA; Ruble MW; Treviño K; Weinstein LM; Gresky DP
Psychiatr Serv; 2017 Feb; 68(2):199-202. PubMed ID: 27691378
[TBL] [Abstract][Full Text] [Related]
27. Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder.
Tsai SJ; Hong CJ; Liou YJ; Chen TJ; Chen ML; Hou SJ; Yen FC; Yu YW
Psychiatry Res; 2009 Sep; 169(2):113-7. PubMed ID: 19700204
[TBL] [Abstract][Full Text] [Related]
28. Sex differences in glutamate receptor gene expression in major depression and suicide.
Gray AL; Hyde TM; Deep-Soboslay A; Kleinman JE; Sodhi MS
Mol Psychiatry; 2015 Sep; 20(9):1057-68. PubMed ID: 26169973
[TBL] [Abstract][Full Text] [Related]
29. [Depressive symptoms during anorexia nervosa: State of the art and consequences for an appropriate use of antidepressants].
Leblé N; Radon L; Rabot M; Godart N
Encephale; 2017 Feb; 43(1):62-68. PubMed ID: 27452149
[TBL] [Abstract][Full Text] [Related]
30. Nitric oxide: Antidepressant mechanisms and inflammation.
Ghasemi M
Adv Pharmacol; 2019; 86():121-152. PubMed ID: 31378250
[TBL] [Abstract][Full Text] [Related]
31. Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression.
Hughes ZA; Neal SJ; Smith DL; Sukoff Rizzo SJ; Pulicicchio CM; Lotarski S; Lu S; Dwyer JM; Brennan J; Olsen M; Bender CN; Kouranova E; Andree TH; Harrison JE; Whiteside GT; Springer D; O'Neil SV; Leonard SK; Schechter LE; Dunlop J; Rosenzweig-Lipson S; Ring RH
Neuropharmacology; 2013 Mar; 66():202-14. PubMed ID: 22551786
[TBL] [Abstract][Full Text] [Related]
32. Identification of MicroRNA-124-3p as a Putative Epigenetic Signature of Major Depressive Disorder.
Roy B; Dunbar M; Shelton RC; Dwivedi Y
Neuropsychopharmacology; 2017 Mar; 42(4):864-875. PubMed ID: 27577603
[TBL] [Abstract][Full Text] [Related]
33. Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial.
Williams LM; Korgaonkar MS; Song YC; Paton R; Eagles S; Goldstein-Piekarski A; Grieve SM; Harris AW; Usherwood T; Etkin A
Neuropsychopharmacology; 2015 Sep; 40(10):2398-408. PubMed ID: 25824424
[TBL] [Abstract][Full Text] [Related]
34. Role of trophic factors GDNF, IGF-1 and VEGF in major depressive disorder: A comprehensive review of human studies.
Sharma AN; da Costa e Silva BF; Soares JC; Carvalho AF; Quevedo J
J Affect Disord; 2016 Jun; 197():9-20. PubMed ID: 26956384
[TBL] [Abstract][Full Text] [Related]
35. Escitalopram: a review of its use in the management of major depressive disorder.
Murdoch D; Keam SJ
Drugs; 2005; 65(16):2379-404. PubMed ID: 16266205
[TBL] [Abstract][Full Text] [Related]
36. Utility of event-related potentials in predicting antidepressant treatment response: An iSPOT-D report.
van Dinteren R; Arns M; Kenemans L; Jongsma ML; Kessels RP; Fitzgerald P; Fallahpour K; Debattista C; Gordon E; Williams LM
Eur Neuropsychopharmacol; 2015 Nov; 25(11):1981-90. PubMed ID: 26282359
[TBL] [Abstract][Full Text] [Related]
37. Genomic predictors of remission to antidepressant treatment in geriatric depression using genome-wide expression analyses: a pilot study.
Eyre HA; Eskin A; Nelson SF; St Cyr NM; Siddarth P; Baune BT; Lavretsky H
Int J Geriatr Psychiatry; 2016 May; 31(5):510-7. PubMed ID: 26471432
[TBL] [Abstract][Full Text] [Related]
38. Glutamate hypothesis of depression and its consequences for antidepressant treatments.
Musazzi L; Treccani G; Popoli M
Expert Rev Neurother; 2012 Oct; 12(10):1169-72. PubMed ID: 23082730
[No Abstract] [Full Text] [Related]
39. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
40. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
Levitan RD; Shen JH; Jindal R; Driver HS; Kennedy SH; Shapiro CM
J Psychiatry Neurosci; 2000 Sep; 25(4):337-46. PubMed ID: 11022398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
